Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00970580 | A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | PHASE1 | COMPLETED | 18 | — | — | Oct 1, 2009 | Sep 1, 2011 | Sep 16, 2013 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| BIIB022 in Combination with Paclitaxel and Carboplatin | EXPERIMENTAL | BIIB022 in Combination with Paclitaxel and Carboplatin |
| Name | Type | Description |
|---|---|---|
| BIIB022 With Paclitaxel and Carboplatin | DRUG | Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin |
Inclusion Criteria: * Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1 Exclusion Criteria: * History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Pri...